Moleculin Biotech, Inc., a clinical stage pharmaceutical company based in Houston, Texas, specializes in developing drugs for tumors and viruses, employing 15 people since its 2016 IPO. The firm focuses on three core technologies, Annamycin, WP1066, and WP1122 portfolios, with six drug candidates, including WP1066 for multiple oncogenic targets and Annamycin for leukemia and sarcoma treatment.
Moleculin Biotech (MBRX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Moleculin Biotech's actual EPS was -$1.70, beating the estimate of -$2.56 per share, resulting in a 33.60% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
